![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
Abstract
Lipid peroxidation (LPO) product accumulation in human tissues is a major cause of tissular and cellular dysfunction that plays a major role in ageing and most age-related and oxidative stress-related diseases. The current evidence for the implication of LPO in pathological processes is discussed in this review. New data and literature review are provided evaluating the role of LPO in the pathophysiology of ageing and classically oxidative stress-linked diseases, such as neurodegenerative diseases, diabetes and atherosclerosis (the main cause of cardiovascular complications). Striking evidences implicating LPO in foetal vascular dysfunction occurring in pre-eclampsia, in renal and liver diseases, as well as their role as cause and consequence to cancer development are addressed.
Keywords::
- Oxidative stress
- oxidative homeostasis
- reactive oxygen species
- lipid peroxidation
- 4-Hydroxynonenal
- neurodegenerative diseases
- Alzheimer's disease
- amyotrophic lateral sclerosis
- Parkinson's disease
- liver disease
- fatty liver
- atherosclerosis
- redox equilibrium
- cell signalling
- oxidized phospholipids
- oxysterol
- diabetes
- diabetes complications
- 4-hydroxydodecadienal
- 4-hydroxynonenal
- pre-eclampsia
- HELLP syndrome
- IUGR
- glutathione
- redox signaling
- Nrf2
- antioxidant enzymes
- foetal endothelium
- renal diseases
- lymphoedema
- hyperglycaemia
- advanced glycation end-products
- cancer
Declaration of interest: This review summarizes in part results of the European networking project denoted COST B35 Action on Lipid Peroxidation Associated Disorders. We gratefully acknowledge supports from INSERM and University Paul Sabatier, Toulouse, France (N. Auge, A. Negre-Salvayre, R. Salvayre), the British Heart Foundation (FS/07/020) (G.E. Mann, S. Chapple, R. Siow), the Croatian Ministry of Science, Education and Sports (N. and K. Zarkovic), the Ministry of Science Health Institute Carlos III (M. Portero-Otin and R. Pamplona), the Ministry of the University (PRIN 2007) and Region of Piedmont (Ric Sanit Final 2008, 2009), Italy (G. Poli), The Yedidut Foundation Mexico, The David R. Bloom Center for Pharmacy and The Dr. Adolf and Klara Brettler Centre for Research in Molecular Pharmacology and Therapeutics at the Hebrew University of Jerusalem (S. Sasson, G. Cohen, Y. Riahi, O. Shamni).
This paper was first published online on Early Online on 1 July 2010.